Ibrutinib and Rituximab vs Standard Chemoimmunotherapy in CLL

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Coverage of stories discussed this week on ascopost.com:

Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL

Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Coverage of stories discussed this week on ascopost.com:

Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL

Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Coverage of stories discussed this week on ascopost.com:

Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL

Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Coverage of stories discussed this week on ascopost.com:

Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL

Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Coverage of stories discussed this week on ascopost.com:

Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL

Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries